China AIDS infection of hepatitis b, a total of map drawing

Study make us find inexpensive new treatment strategies

The 2017-04-13

Source: health

Report from our correspondent (reporter xiao-kun liu Stringer Duan Wenli) Peking union medical college hospital infection medical professor li team mapped HIV/AIDS, hepatitis b virus coinfection of China map, reveal the hepatitis b can accelerate the development process, AIDS infection does not affect curative effect and drug classes hepatotoxicity, and explore the effect of low-price HIV/AIDS, hepatitis b were infected with new treatment strategies. Around the subject, the team has published 14 papers, of which 10 pieces SCI papers. The results of the study was China's HIV/AIDS diagnosis and treatment guidelines for reference; Diagnosis and treatment plan in guangxi and yunnan AIDS application demonstration area, significantly improve the treatment success.

HIV/AIDS and hepatitis b have the same infection, according to data from other countries and regions, 5% ~ 20% of HIV patients with chronic hepatitis b. Li team of 12 provinces of the nation's 1944 HIV infections in the more than 10 years of research, comprehensive evaluation of China's AIDS virus infection of hepatitis b virus and hepatitis c virus (HCV) infection and disease characteristics. , according to the results of the AIDS virus infection of hepatitis b virus and hepatitis c virus (HCV) infection rate was 9.5% and 8.3%, respectively, the total incidence of meteorological north low general situation.

Li further research team found that HIV after the merger of hepatitis b, liver fibrosis index rise, elevated liver enzymes, liver damage is aggravating, at the same time, promote the development process of HIV/AIDS. Previous research has shown that AIDS drug nevirapine in patients with HIV/AIDS merged c hepatotoxicity is bigger, but for the AIDS merged the curative effect of hepatitis b patients and drug side effects need to be confirmed. Project team of 529 people with HIV infection, HIV infections can be divided into single infection and hepatitis b virus infection group, after using the same anti-aids drugs, two similar group of people infected with the AIDS virus inhibition rate. The findings hint, combined hepatitis b does not affect the efficacy of drug classes, nevirapine does not add the merger hepatitis b patients with hepatic toxicity.

Team (drug treatment strategies for the research results show that when the HBV copy number is less than 20000 iu/ml, can use hepatitis b drug lamivudine resistance together with the other two AIDS drugs compatibility. When hepatitis b copy number more than 20000 iu/ml, you can use against hepatitis b drug tenofovir and lamivudine with another kind of anti-aids drug compatibility. The clinical practice, the above drug strategies has the long-term curative effect, and is conducive to the rational allocation of drug resources, total infection patients in the limited resources has an important reference significance.